Table 4.

Body fat composition before and after re-installing SGAs in patients with schizophrenia during a 6-week treatment with olanzapine depending on the presence or absence of MetS [Me (Q1; Q3)].

Time-point for the assessment	Patients with MetS (n = 10)	p-value	Patients without MetS (n = 20)	p-value
Total body fat percentage
At hospitalization	46.5 [36; 53.6]	0.944	31.2 [22.6; 30.0]	0.005*
After a 6-week treatment	45.5 [35.9; 53.7]		35.1 [25.4; 44.1]
Visceral fat level
At hospitalization	13 [9; 18]	0.963	7 [4; 8]	0.034*
After a 6-week treatment	13 [10; 17]		8 [5; 9]
Total fat fold
At hospitalization, mm	119 [102; 146]	0.341	84 [68; 116]	<0.001*
After a 6-week treatment, mm	124 [104; 146]		85 [70; 118]
Waist circumference
At hospitalization, cm	114 [103; 125]	0.105	87 [80; 95]	0.020*
After a 6-week treatment, cm	115 [105; 125]		88 [80; 95]
Body weight
At hospitalization, kg	103.1 [95.0; 119.1]	0.306	73.7 [62.3; 87.9]	0.029*
After a 6-week treatment, kg	103.3 [96.4; 117.6]		74.2 [64; 89.5]
Body mass index
At hospitalization	36.1 [34.5; 37.8]	0.889	25.0 [22.6; 30.0]	0.023*
After a 6-week treatment	36.0 [34.4; 37.8]		26.7 [23.6; 34.1]

*p < 0.05—statistically significant difference. Comparisons between groups were performed using the Wilcoxon signed-rank test.